InsiderSignal.AI

InsiderSignal.ai

RYTM - Rhythm Pharmaceuticals, Inc.

Insider Sale by Smith Hunter C (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

5 days ago, Smith Hunter C, serving as CFO at Rhythm Pharmaceuticals, Inc. (RYTM), sold 7,954 shares at $101.31 per share, for a total transaction value of $805,814.00. Following this transaction, Smith Hunter C now holds 110,512 shares of RYTM.

This sale represents a 7.00% decrease in Smith Hunter C's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, February 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 19, 2026, 2 days after the trade was made.

Rhythm Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Smith Hunter C

CFO

Hunter C. Smith is an individual and the Chief Financial Officer (CFO) and Treasurer of Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company focused on rare neuroendocrine diseases, since August 2017.[[1]](https://www.fiercebiotechweek.com/event/contact/hunter-smith)[[2]](https://www.vanquabio.com/team/hunter-smith/)[[3]](https://fintool.com/app/research/companies/RYTM/people/hunter-smith) Aged 57, he previously served as interim CEO from March to July 2020, leading the company through FDA submissions and market challenges.[[1]](https://www.fiercebiotechweek.com/event/contact/hunter-smith)[[2]](https://www.vanquabio.com/team/hunter-smith/)[[3]](https://fintool.com/app/research/companies/RYTM/people/hunter-smith) Under his tenure, Smith orchestrated the company's initial public offering and raised over $1 billion in capital, significantly contributing to corporate strategy and growth in rare disease therapeutics.[[1]](https://www.fiercebiotechweek.com/event/contact/hunter-smith)[[2]](https://www.vanquabio.com/team/hunter-smith/) With over 30 years of global finance and management experience across industries, Smith joined Rhythm from Celgene Corporation, where he was Vice President of Finance and CFO of the Inflammation and Immunology Business Unit, overseeing the global launch of Otezla® and the integration of Receptos, Inc..[[1]](https://www.fiercebiotechweek.com/event/contact/hunter-smith)[[2]](https://www.vanquabio.com/team/hunter-smith/) He has recently engaged in insider trading, selling shares worth approximately $702,744 in early February 2026, and is scheduled to speak at the Guggenheim Emerging Outlook: Biotech Summit 2026.[[4]](https://www.quiverquant.com/news/Rhythm+Pharmaceuticals'+CFO+Hunter+C.+Smith+to+Speak+at+Guggenheim+Emerging+Outlook:+Biotech+Summit+2026)[[5]](https://www.investing.com/news/insider-trading-news/smith-rhythm-pharmaceuticals-cfo-sells-702k-in-rytm-stock-93CH-4492254)

View full insider profile →

Trade Price

$101.31

Quantity

7,954

Total Value

$805,814.00

Shares Owned

110,512

Trade Date

Tuesday, February 17, 2026

5 days ago

SEC Filing Date

Thursday, February 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Rhythm Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning RYTM

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4130351

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime